Compare QUCY & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QUCY | MITQ |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Germany | United States |
| Employees | 13 | N/A |
| Industry | | Telecommunications Equipment |
| Sector | | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.9M |
| IPO Year | 2021 | 2019 |
| Metric | QUCY | MITQ |
|---|---|---|
| Price | $0.51 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 346.5K | ★ 416.7K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $20,139,000.00 |
| Revenue This Year | $74.34 | N/A |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | ★ N/A | $67.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.42 |
| 52 Week High | $0.74 | $1.66 |
| Indicator | QUCY | MITQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 65.48 |
| Support Level | $0.43 | $0.62 |
| Resistance Level | $0.53 | $0.79 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 28.54 | 63.33 |
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.